PSNL实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 04:00):
Our systems believe the stock currently is overvalued by -0.02% compare to its pairs and should correct downwards.

Stats
今日成交量	125 339
平均成交量	227 887
市值	60.77M
EPS	$-0.260 ( Q1 \| 2024-05-08 )
下一个收益日期	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.620 (Sector) 42.63 (Industry) 0
ATR14	$0.00500 (0.43%)

ACRS -0.90%

AKU -17.87%

APDN -0.73%

BDSX 2.00%

BIOC 0.00%

BNGO -7.69%

BNR 1.05%

CDNA 7.92%

CEMI 0.22%

CHEK -0.99%

CNTG -3.80%

CSTL 2.88%

DMTK -11.32%

DRIO 1.71%

EXAS -5.03%

FLDM -7.02%

FLGT -2.39%

GENE 1.35%

GH -0.59%

GTH 0.12%

HTGM 0.00%

ICLR 0.08%

IDXX -1.37%

ILMN -1.95%

ISPC -1.87%

LAB 0.00%

LMDX 0.00%

MDXH 0.84%

ME -7.58%

MEDP -2.94%

MYGN 0.62%

MYNZ -14.13%

NDRA -5.73%

NEO 3.97%

NEOG -2.07%

NOTV -4.05%

NTRA -1.56%

OCDX 0.92%

OLK 0.75%

OPGN 0.39%

OPK -0.79%

PMD 2.11%

PRPO 4.85%

PSNL -3.31%

RDNT 0.03%

SERA 3.50%

SHC -0.25%

SQL 0.00%

STIM -1.10%

STRR 2.71%

STRRP 8.67%

SYNH 0.02%

TRIB 2.90%

TTOO -1.66%

TWST 3.79%

VIVO 0.00%

XGN -1.62%

Insider Trading

Date	Person	Action	Amount	type
2024-06-17	Chen Richard	Sell	5 055	Common Stock
2024-06-17	Tachibana Aaron	Sell	7 176	Common Stock
2024-06-17	Moore Stephen Michael	Sell	1 585	Common Stock
2024-05-17	Myers Woodrow A Jr	Buy	50 000	Stock Option (right to buy)
2024-05-17	Shoff Lonnie	Buy	50 000	Stock Option (right to buy)

INSIDER POWER
-59.51
Last 98 transactions
Buy: 4 067 705 \| Sell: 9 658 662

相关性 (AI algo v.1.1b): Overvalued: -0.02% $1.170 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: 0.11 (neutral)

短: -0.82 (strong negative)

Signal:(41.026) Neutral

Personalis Inc 相关性

10 最正相关
EXFY	0.819

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Personalis Inc 相关性 - 货币/商品

0.12
( neutral )

-0.16
( neutral )

0.00
( neutral )

-0.49
( neutral )

Personalis Inc 财务报表

Annual	2023
营收:	$73.48M
毛利润:	$18.21M (24.78 %)
EPS:	$-2.25

FY	2023
营收:	$73.48M
毛利润:	$18.21M (24.78 %)
EPS:	$-2.25

FY	2022
营收:	$65.05M
毛利润:	$13.35M (20.52 %)
EPS:	$-2.48

FY	2021
营收:	$85.49M
毛利润:	$31.66M (37.03 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Personalis Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Personalis Inc

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.